Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696571 | 0.90 | MAPK1 (0.51) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL13857264 | 0.87 | MAPK1 (0.53) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL4342719 | 0.87 | PDE3B (0.48) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL696762 | 0.85 | MAPK1 (0.54) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL2052824 | 0.81 | KDM4E (0.47) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL698276 | 0.78 | MAPK1 (0.56) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL21809613 | 0.75 | ALDH1A1 (0.48) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL21810159 | 0.75 | ALDH1A1 (0.48) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL21843980 | 0.75 | ALDH1A1 (0.48) | PDE3BPDE3AMAPK1GAAALDH1A1 | |
| SCHEMBL695681 | 0.75 | MAPK1 (0.43) | PDE3BPDE3AMAPK1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | claimed |
| EP-2227469-B9 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-2227469-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| WO-2011067356-A2 | POLYMORPHS OF A MEK INHIBITOR | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067348-A2 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067348-A2 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067356-A2 | POLYMORPHS OF A MEK INHIBITOR | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| EP-2227469-A1 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | PDE3B 1071/4885PDE3A 1069/4885MAPK1 1/4885 |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | PDE3B 1543/4885PDE3A 2234/4885MAPK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.